Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All patients must have a diagnosis of T2DM and be currently treated with metformin~* Patients in the study must have a HbA1c between \>=7 and \<=10.5%~* Patients must have a fasting plasma glucose (FPG) \<270 mg/dL (15 mmol/L)~Exclusion Criteria:~* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, diabetes secondary to pancreatitis or pancreatectomy, or a severe hypoglycemic episode within 6 months before screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Canagliflozin 50 mg bid (Type: EXPERIMENTAL): Each patient will receive 50 mg canagliflozin twice daily for 18 weeks.
- Canagliflozin 150 mg bid (Type: EXPERIMENTAL): Each patient will receive 150 mg canagliflozin twice daily for 18 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Each patient will receive matching placebo twice daily for 18 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).